GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Other Current Receivables

BioLine Rx (XTAE:BLRX) Other Current Receivables : ₪1.26 Mil (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Other Current Receivables?

BioLine Rx's Other Current Receivables for the quarter that ended in Sep. 2024 was ₪1.26 Mil.

BioLine Rx's quarterly Other Current Receivables increased from Mar. 2024 (₪1.83 Mil) to Jun. 2024 (₪2.36 Mil) but then stayed the same from Jun. 2024 (₪2.36 Mil) to Sep. 2024 (₪1.26 Mil).

BioLine Rx's annual Other Current Receivables increased from Dec. 2021 (₪0.51 Mil) to Dec. 2022 (₪2.60 Mil) but then declined from Dec. 2022 (₪2.60 Mil) to Dec. 2023 (₪1.26 Mil).


BioLine Rx Other Current Receivables Historical Data

The historical data trend for BioLine Rx's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Other Current Receivables Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.21 0.51 0.51 2.60 1.26

BioLine Rx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.14 1.26 1.83 2.36 1.26

BioLine Rx Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


BioLine Rx Other Current Receivables Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx Headlines

From GuruFocus

Q2 2020 BioLine RX Ltd Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q4 2022 BioLine RX Ltd Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q3 2022 BioLine RX Ltd Earnings Call Transcript

By GuruFocus Research 02-06-2024

BioLine RX Ltd APHEXDA Investor Conference Call Transcript

By GuruFocus Research 02-06-2024

Q1 2023 BioLine RX Ltd Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q2 2024 BioLine RX Ltd Earnings Call Transcript

By GuruFocus News 10-09-2024

Q3 2024 BioLine RX Ltd Earnings Call Transcript

By GuruFocus News 11-26-2024